@article{dbabd6b18cb5447bbf81877b5a6209c9,
title = "Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America",
abstract = "It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.",
keywords = "HIV-1, HIV-associated nephropathy, chronic kidney disease, clinical practice guideline, kidney transplantation.",
author = "Lucas, {Gregory M.} and Ross, {Michael J.} and Stock, {Peter G.} and Shlipak, {Michael G.} and Wyatt, {Christina M.} and Gupta, {Samir K.} and Atta, {Mohamed G.} and Wools-Kaloustian, {Kara K.} and Pham, {Paul A.} and Bruggeman, {Leslie A.} and Lennox, {Jeffrey L.} and Ray, {Patricio E.} and Kalayjian, {Robert C.}",
note = "Funding Information: Financial support. Support for this guideline was provided by the Infectious Diseases Society of America. The following authors were supported by the National Institutes of Health (NIH): G. M. L. (grant numbers R01 DA026770, K24 DA035684, and P30 AI094189); L. A. B (AI 036219); M. J. R., C. M. W., and M. G. A. (PO1 DK 056492); M. A. R (RO1 KD 078510); J. L. L (P30 AI050409); R. C. K. (AI 69501, AI 036219). Support was also received from the Veterans Administration: VISN10 Geriatric Research Educational and Clinical Centers, Louis Stokes Cleveland Veterans Administration Medical Center. Funding Information: Potential conflicts of interest. The following list is a reflection of what has been reported to IDSA. To provide thorough transparency, IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest (COI) is determined by a review process that includes assessment by the SPGC Chair, the SPGC liaison to the development panel, and the Board of Directors liaison to the SPGC and, if necessary, the COI Task Force of the Board. This assessment of disclosed relationships for possible COI will be based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. For activities outside of the submitted work, G. M. L. was a paid member of the data safety and monitoring committee for BioAlliance Pharma (ended June 2008). For activities outside of the submitted work, R. C. K. has received research grants from Gilead, Schering-Plough, and Pfizer. For activities outside of the submitted work, M. G. A. served as a consultant for Amgen, Genzyme, and Bristol-Myers Squibb; received honoraria from Amgen and Genzyme; and received research grants from Amgen. For activities outside of the submitted work, L. A. B. received research grants from NIH. For activities outside of the submitted work, S. K. G. has served as a consultant for Bristol-Myers Squibb and has received research grants from NIH, Merck & Co, Janssen Therapeutics, and Gilead Sciences. For activities outside of the submitted work, J. L. L. has served as a consultant for Merck Inc and received research grants from the National Institute of Allergy and Infectious Diseases, Pfizer, and Merck Inc. For activities outside of the submitted work, P. A. P. has served as a consultant for Barclay and the Maryland AIDS Drug Assistance Program. For activities outside of the submitted work, P. G. S. received research grants from NIH and Juvenile Diabetes Research Foundation. For activities outside of the submitted work, M. J. R. has served as a consultant for Gerson Lehrman Group. For activities outside of the submitted work, C. M. W. has served as a consultant for Biocryst Pharmaceuticals and received research grants from NIH, Gilead Sciences, and Gilead Foundation. All other authors report no potential conflicts. Publisher Copyright: {\textcopyright} 2014 The Author.",
year = "2014",
month = nov,
day = "1",
doi = "10.1093/cid/ciu730",
language = "English (US)",
volume = "59",
pages = "1203--1207",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",
}